Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Abstract The coronavirus disease (COVID-19) pandemic has led to a global struggle to cope with the sheer numbers of infected persons, many of whom require intensive care support or eventually succumb to the illness. The outbreak is managed by a combination of disease containment via public health me...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | Military Medical Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40779-020-00251-x |
id |
doaj-42669d87f6ba4d47bb24a03f9703b033 |
---|---|
record_format |
Article |
spelling |
doaj-42669d87f6ba4d47bb24a03f9703b0332020-11-25T02:12:11ZengBMCMilitary Medical Research2054-93692020-05-017111810.1186/s40779-020-00251-xRole of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelinesXinni Xu0Yew Kwang Ong1De Yun Wang2Department of Otolaryngology-Head and Neck Surgery, National University Hospital SystemDepartment of Otolaryngology-Head and Neck Surgery, National University Hospital SystemDepartment of Otolaryngology, Yong Loo Lin School of Medicine, National University of SingaporeAbstract The coronavirus disease (COVID-19) pandemic has led to a global struggle to cope with the sheer numbers of infected persons, many of whom require intensive care support or eventually succumb to the illness. The outbreak is managed by a combination of disease containment via public health measures and supportive care for those who are affected. To date, there is no specific anti-COVID-19 treatment. However, the urgency to identify treatments that could turn the tide has led to the emergence of several investigational drugs as potential candidates to improve outcome, especially in the severe to critically ill. While many of these adjunctive drugs are being investigated in clinical trials, professional bodies have attempted to clarify the setting where the use of these drugs may be considered as off-label or compassionate use. This review summarizes the clinical evidence of investigational adjunctive treatments used in COVID-19 patients as well as the recommendations of their use from guidelines issued by international and national organizations in healthcare.http://link.springer.com/article/10.1186/s40779-020-00251-xCOVID-19Adjunctive treatmentChloroquineLopinavir-ritonavirRemdesivirCorticosteroids |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xinni Xu Yew Kwang Ong De Yun Wang |
spellingShingle |
Xinni Xu Yew Kwang Ong De Yun Wang Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines Military Medical Research COVID-19 Adjunctive treatment Chloroquine Lopinavir-ritonavir Remdesivir Corticosteroids |
author_facet |
Xinni Xu Yew Kwang Ong De Yun Wang |
author_sort |
Xinni Xu |
title |
Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines |
title_short |
Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines |
title_full |
Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines |
title_fullStr |
Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines |
title_full_unstemmed |
Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines |
title_sort |
role of adjunctive treatment strategies in covid-19 and a review of international and national clinical guidelines |
publisher |
BMC |
series |
Military Medical Research |
issn |
2054-9369 |
publishDate |
2020-05-01 |
description |
Abstract The coronavirus disease (COVID-19) pandemic has led to a global struggle to cope with the sheer numbers of infected persons, many of whom require intensive care support or eventually succumb to the illness. The outbreak is managed by a combination of disease containment via public health measures and supportive care for those who are affected. To date, there is no specific anti-COVID-19 treatment. However, the urgency to identify treatments that could turn the tide has led to the emergence of several investigational drugs as potential candidates to improve outcome, especially in the severe to critically ill. While many of these adjunctive drugs are being investigated in clinical trials, professional bodies have attempted to clarify the setting where the use of these drugs may be considered as off-label or compassionate use. This review summarizes the clinical evidence of investigational adjunctive treatments used in COVID-19 patients as well as the recommendations of their use from guidelines issued by international and national organizations in healthcare. |
topic |
COVID-19 Adjunctive treatment Chloroquine Lopinavir-ritonavir Remdesivir Corticosteroids |
url |
http://link.springer.com/article/10.1186/s40779-020-00251-x |
work_keys_str_mv |
AT xinnixu roleofadjunctivetreatmentstrategiesincovid19andareviewofinternationalandnationalclinicalguidelines AT yewkwangong roleofadjunctivetreatmentstrategiesincovid19andareviewofinternationalandnationalclinicalguidelines AT deyunwang roleofadjunctivetreatmentstrategiesincovid19andareviewofinternationalandnationalclinicalguidelines |
_version_ |
1724911016908685312 |